RudaCure Inc., which develops treatments for intractable diseases, was a annoncé as a final selection for the Ministère de SMEs and Startups' Startup Leap Forward Package Program on April 28th.
This program funding devrait be utilized for research on commercializing the peptide drug for traitement de la douleur actuellement under development, ainsi que for external promotion activities.
This devrait serve as the starting point for RudaCure Inc., which is entering its fifth year since founding, to take a leap forward.
Starting with this program, RudaCure a achevé all preparations for essais cliniques of the traitement de la sécheresse oculaire and ocular mucosal damage treatment actuellement under development, and will begin full-scale reagent production for essais cliniques starting next month.
De plus, a busy schedule of commercialization activities is planned, notamment BIO KOREA in May, the presentation of RCI002 résultats précliniques for chemotherapy-induced traitement de la douleur at ASCO in June, and attendance at BIO USA.
At BIO KOREA, meetings are scheduled with companies showing potential as multinational partners for RCI002,
and at BIO USA, collaboration with multinational partners interested in développement de médicaments vétérinaires is also anticipated, offering a chance to witness de l'entreprise rapid growth.
